Harvard Bioscience Reports Q4 Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy HBIO?
Source: seekingalpha
- Earnings Report: Harvard Bioscience reported a Q4 GAAP EPS of -$0.06 with revenues of $23.7 million, reflecting a 3.7% year-over-year decline, indicating pressure on the company's market competitiveness and profitability challenges.
- Future Guidance: The company expects Q1 2026 revenue between $20.0 million and $22.0 million, below the consensus estimate of $23.1 million, reflecting a cautious outlook on future performance.
- Gross Margin Expectations: Adjusted gross margin is projected to be between 57% and 59%, indicating efforts in cost control and profitability, yet still requiring attention to market conditions.
- EBITDA Forecast: Adjusted EBITDA is anticipated to range from $1.0 million to $2.2 million, highlighting challenges in restoring profitability, which may impact investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HBIO
Wall Street analysts forecast HBIO stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.090
Low
2.00
Averages
2.00
High
2.00
Current: 5.090
Low
2.00
Averages
2.00
High
2.00
About HBIO
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Harvard Bioscience Q4 2025 Earnings Call Insights
- Strong Financial Performance: Harvard Bioscience reported Q4 2025 revenue of $23.7 million with a gross margin of 60% and adjusted EBITDA of $3.8 million, reflecting a 27% year-over-year growth, indicating successful transformation towards higher-margin product lines.
- Strategic Consolidation Plan: The company announced the closure of the Holliston facility, consolidating operations into Minneapolis and European centers, expected to save $3 million by 2027, enhancing operational efficiency and resource optimization.
- Positive Outlook: CFO Mark Frost projected low single-digit revenue growth and high single-digit adjusted EBITDA growth for 2026, primarily driven by higher-margin new product introductions, demonstrating confidence in the translational science market.
- Governance Changes: The appointment of new CFO Mark Frost and four new board members signifies a strengthening of the governance structure, aimed at supporting the company's strategic transformation and sustained growth.
See More
Harvard Bioscience Reports Q4 Earnings
- Earnings Report: Harvard Bioscience reported a Q4 GAAP EPS of -$0.06 with revenues of $23.7 million, reflecting a 3.7% year-over-year decline, indicating pressure on the company's market competitiveness and profitability challenges.
- Future Guidance: The company expects Q1 2026 revenue between $20.0 million and $22.0 million, below the consensus estimate of $23.1 million, reflecting a cautious outlook on future performance.
- Gross Margin Expectations: Adjusted gross margin is projected to be between 57% and 59%, indicating efforts in cost control and profitability, yet still requiring attention to market conditions.
- EBITDA Forecast: Adjusted EBITDA is anticipated to range from $1.0 million to $2.2 million, highlighting challenges in restoring profitability, which may impact investor confidence.
See More
Harvard Bioscience Announces 1-for-10 Reverse Stock Split
- Reverse Stock Split Announcement: Harvard Bioscience has announced a 1-for-10 reverse stock split effective March 13, 2026, reducing the outstanding shares from approximately 44.7 million to 4.47 million, which may impact the company's stock price and market perception.
- Stock Price Decline: Following the announcement, HBIO shares fell roughly 12.76% in overnight trading, dropping from $0.55 to $0.47, indicating a negative market reaction and a potential decline in investor confidence.
- Authorized Shares Unchanged: The company noted that the reverse split will not alter the total number of authorized shares, and proportional adjustments will be made to outstanding stock options, warrants, and convertible securities to maintain equity fairness among shareholders.
- Upcoming Earnings Report: Harvard Bioscience is scheduled to report its fourth-quarter financial results on March 12, 2026, before market open, and investors will closely monitor these results to assess the potential impact of the reverse split on the company's future performance.
See More
Harvard Bioscience Approves 1-for-10 Reverse Stock Split
- Reverse Split Decision: Harvard Bioscience approved a 1-for-10 reverse stock split following shareholder authorization at a special meeting on March 6, 2026, aimed at increasing the share price to meet Nasdaq's minimum bid requirement.
- Effective Date: The reverse split will take effect on March 13, 2026, reducing the company's outstanding shares from approximately 44.72 million to about 4.47 million, while the total authorized share count will remain unchanged.
- Market Reaction: Following the announcement of the reverse split, Harvard Bioscience's shares fell by 4.19%, indicating a cautious market response that may affect investor confidence in the company's future.
- Compliance Challenges: The primary goal of this reverse split is to restore compliance with Nasdaq regulations, highlighting the pressures the company faces in the current market environment and its commitment to enhancing shareholder value.
See More
HARVARD BIOSCIENCE DECLARES REVERSE STOCK SPLIT
Harvard Bioscience Announcement: Harvard Bioscience has announced a reverse stock split to enhance its stock price and attract more investors.
Reason for the Split: The reverse stock split is intended to improve the company's market perception and comply with listing requirements.
Impact on Shareholders: Shareholders will see a reduction in the number of shares they own, but the overall value of their investment should remain the same.
Future Outlook: The company aims to leverage this move to strengthen its financial position and support future growth initiatives.
See More
Harvard Bioscience to Participate in Virtual Healthcare Forum
- Executive Participation: Harvard Bioscience's CEO John Duke and Interim CFO Mark Frost will participate in KeyBanc Capital Markets' Virtual Healthcare Forum on March 17, showcasing the company's leadership in life sciences.
- Webcast Arrangement: The fireside chat will be broadcast at 2:15 PM ET on the company's investor relations website, allowing global investors and stakeholders to engage, thereby enhancing transparency and interaction.
- Company Background: Harvard Bioscience focuses on developing, manufacturing, and selling technologies and products for life science applications, with clients including renowned academic institutions and leading pharmaceutical and biotechnology companies, highlighting its significance in the industry.
- Global Business Presence: The company operates in the U.S., Europe, and China, selling through direct and distribution channels to customers worldwide, indicating its extensive influence and business expansion capabilities in international markets.
See More
Harvard Bioscience Q4 2025 Earnings Call Insights
- Strong Financial Performance: Harvard Bioscience reported Q4 2025 revenue of $23.7 million with a gross margin of 60% and adjusted EBITDA of $3.8 million, reflecting a 27% year-over-year growth, indicating successful transformation towards higher-margin product lines.
- Strategic Consolidation Plan: The company announced the closure of the Holliston facility, consolidating operations into Minneapolis and European centers, expected to save $3 million by 2027, enhancing operational efficiency and resource optimization.
- Positive Outlook: CFO Mark Frost projected low single-digit revenue growth and high single-digit adjusted EBITDA growth for 2026, primarily driven by higher-margin new product introductions, demonstrating confidence in the translational science market.
- Governance Changes: The appointment of new CFO Mark Frost and four new board members signifies a strengthening of the governance structure, aimed at supporting the company's strategic transformation and sustained growth.
See More
Harvard Bioscience Reports Q4 Earnings
- Earnings Report: Harvard Bioscience reported a Q4 GAAP EPS of -$0.06 with revenues of $23.7 million, reflecting a 3.7% year-over-year decline, indicating pressure on the company's market competitiveness and profitability challenges.
- Future Guidance: The company expects Q1 2026 revenue between $20.0 million and $22.0 million, below the consensus estimate of $23.1 million, reflecting a cautious outlook on future performance.
- Gross Margin Expectations: Adjusted gross margin is projected to be between 57% and 59%, indicating efforts in cost control and profitability, yet still requiring attention to market conditions.
- EBITDA Forecast: Adjusted EBITDA is anticipated to range from $1.0 million to $2.2 million, highlighting challenges in restoring profitability, which may impact investor confidence.
See More
Harvard Bioscience Announces 1-for-10 Reverse Stock Split
- Reverse Stock Split Announcement: Harvard Bioscience has announced a 1-for-10 reverse stock split effective March 13, 2026, reducing the outstanding shares from approximately 44.7 million to 4.47 million, which may impact the company's stock price and market perception.
- Stock Price Decline: Following the announcement, HBIO shares fell roughly 12.76% in overnight trading, dropping from $0.55 to $0.47, indicating a negative market reaction and a potential decline in investor confidence.
- Authorized Shares Unchanged: The company noted that the reverse split will not alter the total number of authorized shares, and proportional adjustments will be made to outstanding stock options, warrants, and convertible securities to maintain equity fairness among shareholders.
- Upcoming Earnings Report: Harvard Bioscience is scheduled to report its fourth-quarter financial results on March 12, 2026, before market open, and investors will closely monitor these results to assess the potential impact of the reverse split on the company's future performance.
See More
Harvard Bioscience Approves 1-for-10 Reverse Stock Split
- Reverse Split Decision: Harvard Bioscience approved a 1-for-10 reverse stock split following shareholder authorization at a special meeting on March 6, 2026, aimed at increasing the share price to meet Nasdaq's minimum bid requirement.
- Effective Date: The reverse split will take effect on March 13, 2026, reducing the company's outstanding shares from approximately 44.72 million to about 4.47 million, while the total authorized share count will remain unchanged.
- Market Reaction: Following the announcement of the reverse split, Harvard Bioscience's shares fell by 4.19%, indicating a cautious market response that may affect investor confidence in the company's future.
- Compliance Challenges: The primary goal of this reverse split is to restore compliance with Nasdaq regulations, highlighting the pressures the company faces in the current market environment and its commitment to enhancing shareholder value.
See More
HARVARD BIOSCIENCE DECLARES REVERSE STOCK SPLIT
Harvard Bioscience Announcement: Harvard Bioscience has announced a reverse stock split to enhance its stock price and attract more investors.
Reason for the Split: The reverse stock split is intended to improve the company's market perception and comply with listing requirements.
Impact on Shareholders: Shareholders will see a reduction in the number of shares they own, but the overall value of their investment should remain the same.
Future Outlook: The company aims to leverage this move to strengthen its financial position and support future growth initiatives.
See More
Harvard Bioscience to Participate in Virtual Healthcare Forum
- Executive Participation: Harvard Bioscience's CEO John Duke and Interim CFO Mark Frost will participate in KeyBanc Capital Markets' Virtual Healthcare Forum on March 17, showcasing the company's leadership in life sciences.
- Webcast Arrangement: The fireside chat will be broadcast at 2:15 PM ET on the company's investor relations website, allowing global investors and stakeholders to engage, thereby enhancing transparency and interaction.
- Company Background: Harvard Bioscience focuses on developing, manufacturing, and selling technologies and products for life science applications, with clients including renowned academic institutions and leading pharmaceutical and biotechnology companies, highlighting its significance in the industry.
- Global Business Presence: The company operates in the U.S., Europe, and China, selling through direct and distribution channels to customers worldwide, indicating its extensive influence and business expansion capabilities in international markets.
See More
